ERBB2 and breast carcinoma: HER2 is overexpressed more than 10 times in tumor cells than that in normal cells in 15–30% of all breast cancers [2,5,6,7], 2–66% of all ovarian cancers [8,9], and 4–35% of all lung adenocarcinoma [10,11].